Samrat Pharmachem Ltd Financials
Company Logo

Samrat Pharmachem Ltd Financial Statement

Samrat Pharmachem Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue76.34
Operating Expense75.53
Net Profit-0.23
Net Profit Margin-0.30
Earning Per Share-0.74
EBIDTA0.38
Effective Tax RateTBA

Samrat Pharmachem Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual285.86
Operating Expenses Annual275.62
Operating Profit Annual11.21
Interest Annual0.67
Depreciation0.65
Net Profit Annual7.11
Tax Annual2.77

Samrat Pharmachem Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning9.67
Cash Flow from Operations-10.09
Cash Flow from InvestingTBA
Cash Flow from Financing0.48
Cash Flow at the End0.05

Samrat Pharmachem Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)3.92
PBIT Margin (%)3.69
PBT Margin (%)-1.82
Net PROFIT Margin (%)2.49
Return On Networth / Equity (%)10.39
Return On Networth /Employed (%)13.60
Return On Assets (%)9.15
Total Debt / Equity (X)0.13
Asset Turnover Ratio (%)3.68

Samrat Pharmachem Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual10.48
Total Current Assets Annual103.36
Non Current Assets Annual18.13
Total Shareholders Funds Annual71.80
Total Assets Annual121.49

Samrat Pharmachem Ltd Earning Calls

No Data Availabe

FAQS on Samrat Pharmachem Ltd Financials

As of Sep 13, 2025, Samrat Pharmachem Ltd has a market capitalization of 96.63 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Samrat Pharmachem Ltd is with a debt-to-equity ratio of 0.14.

In FY 2024 , Samrat Pharmachem Ltd recorded a total revenue of approximately 285.86 Cr marking a significant milestone in the company's financial performance.

Samrat Pharmachem Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and -0.0% annually, respectively..

Samrat Pharmachem Ltd's current PE ratio is 13.59.

Samrat Pharmachem Ltd's ROCE averaged 15.4% from the FY ending March 2023 to 2025, with a median of 12.9%. It peaked at 29.0% in March 2023, reflecting strong capital efficiency over the period..

Samrat Pharmachem Ltd's latest EBIT is Rs. 10.56 Cr, surpassing the average EBIT of Rs. 12.51 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions